Literature DB >> 30053074

Randomized Trial of Exercise on Quality of Life in Women With Ovarian Cancer: Women's Activity and Lifestyle Study in Connecticut (WALC).

Yang Zhou1,2, Brenda Cartmel1,2, Linda Gottlieb2, Elizabeth A Ercolano2, Fangyong Li2, Maura Harrigan2, Ruth McCorkle1,3, Jennifer A Ligibel4, Vivian E von Gruenigen5, Radhika Gogoi6, Peter E Schwartz7, Harvey A Risch1,2, Melinda L Irwin1,2.   

Abstract

Background: Ovarian cancer survivors experience a wide range of treatment side effects that can negatively affect health-related quality of life (HRQOL). Physical activity has been shown to improve HRQOL and cancer-related fatigue (CRF) for other cancer survivors; however, no large randomized controlled trial (RCT) has been conducted for ovarian cancer.
Methods: This study examined the impact of a six-month RCT of exercise vs attention control on change in HRQOL (Short Form Health Survey-36) and CRF (Functional Assessment of Cancer Therapy-Fatigue Scale) in ovarian cancer survivors. Women (n = 144) were randomly assigned to study arms between May 1, 2010, and March 20, 2014. All statistical tests were two-sided.
Results: A total of 74 women were randomly assigned to exercise and 70 to attention control. A total of 113 (78.5%) of the participants completed the six-month assessment. Adherence to the exercise intervention was excellent (166.0±66.1 minutes/week in the exercise arm). At six months, women in the exercise arm had improved physical HRQOL (SF-36 Physical Component Summary Score) compared with the control arm, 1.8 (SD = 1.1) vs -2.0 (SD = 1.2) , respectively (group difference = 3.7, SD = 1.2, 95% confidence interval [CI] = 0.7 to 6.8, P = .02). No group differences were seen for change in mental HRQOL. There was a statistically significant improvement in the fatigue score (Functional Assessment of Cancer Therapy-Fatigue) for exercisers (4.0, SD = 1.1, 95% CI = 1.8 to 6.2, P < .001) but not for controls (1.2, SD = 1.2, 95% CI = -1.1 to 3.5, P = .31), with a between-group difference of 2.8 (SD = 1.5, 95% CI = -0.2 to 5.7, P = .06). Conclusions: We found a six-month home-based, telephone-delivered exercise intervention of primarily brisk walking to be associated with improved physical HRQOL in women with ovarian cancer. Given that higher HRQOL and exercise have both been associated with overall survival in women diagnosed with ovarian cancer, oncologists and primary care providers should recommend and refer women diagnosed with ovarian cancer to clinic- or community-based exercise programs.

Entities:  

Mesh:

Year:  2017        PMID: 30053074      PMCID: PMC6515522          DOI: 10.1093/jnci/djx072

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  9 in total

1.  Effect of exercise on body composition among women with ovarian cancer.

Authors:  Anlan Cao; Brenda Cartmel; Fang-Yong Li; Linda T Gottlieb; Maura Harrigan; Jennifer A Ligibel; Radhika Gogoi; Peter E Schwartz; Melinda L Irwin; Leah M Ferrucci
Journal:  J Cancer Surviv       Date:  2022-04-04       Impact factor: 4.062

2.  Interactions between physical activity and type of cancer treatment received on associations with psychosocial outcomes among gynecologic cancer survivors.

Authors:  Ashley E Stenzel; Lauren Thomaier; Patricia I Jewett; Allison C Dona; Katherine Brown; Rachael Gotlieb; Anne Blaes; Deanna Teoh; Rachel I Vogel
Journal:  Gynecol Oncol       Date:  2022-05-05       Impact factor: 5.304

3.  Randomized trial of exercise on depressive symptomatology and brain derived neurotrophic factor (BDNF) in ovarian cancer survivors: The Women's Activity and Lifestyle Study in Connecticut (WALC).

Authors:  Brenda Cartmel; Meghan Hughes; Elizabeth A Ercolano; Linda Gottlieb; Fangyong Li; Yang Zhou; Maura Harrigan; Jennifer A Ligibel; Vivian E von Gruenigen; Radhika Gogoi; Peter E Schwartz; Harvey A Risch; Lingeng Lu; Melinda L Irwin
Journal:  Gynecol Oncol       Date:  2021-03-26       Impact factor: 5.482

4.  Input from multiple stakeholder levels prioritizes targets for improving implementation of an exercise intervention for rural women cancer survivors.

Authors:  Haiyan Qu; Richard Shewchuk; Xuejun Hu; Ana A Baumann; Michelle Y Martin; Maria Pisu; Robert A Oster; Laura Q Rogers
Journal:  Implement Sci Commun       Date:  2020-11-04

5.  Home-based Physical Activity to Alleviate Fatigue in Cancer Survivors: A Systematic Review and Meta-analysis.

Authors:  Famke Huizinga; Nico-Derk Lodewijk Westerink; Annette J Berendsen; Annemiek M E Walenkamp; Mathieu H G DE Greef; Juliët K Oude Nijeweeme; Geertruida H DE Bock; Marjolein Y Berger; Daan Brandenbarg
Journal:  Med Sci Sports Exerc       Date:  2021-12-01       Impact factor: 5.411

Review 6.  Exercise Interventions for Women with Ovarian Cancer: A Realist Review.

Authors:  Deirdre McGrath; Peter O'Halloran; Gillian Prue; Malcolm Brown; Joanne Millar; Adrina O'Donnell; Lisa McWilliams; Claire Murphy; Gwyneth Hinds; Joanne Reid
Journal:  Healthcare (Basel)       Date:  2022-04-13

7.  Development of healthy lifestyle consciousness index for gynecological cancer patients.

Authors:  Nozomi Higashiyama; Ken Yamaguchi; Yosuke Yamamoto; Akihiko Ueda; Yoshihide Inayama; Miho Egawa; Koji Yamanoi; Mana Taki; Masayo Ukita; Yuko Hosoe; Akihito Horie; Junzo Hamanishi; Masaki Mandai
Journal:  Support Care Cancer       Date:  2022-06-08       Impact factor: 3.359

8.  Bibliometric analysis of hotspots and frontiers in cancer-related fatigue among ovarian cancer survivors.

Authors:  Yuanxia Liu; Qianxia Liu; Xiaolian Jiang
Journal:  PLoS One       Date:  2022-09-22       Impact factor: 3.752

Review 9.  Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations.

Authors:  Sarah M Temkin; Matthew P Smeltzer; Monique D Dawkins; Leigh M Boehmer; Leigha Senter; Destin R Black; Stephanie V Blank; Anna Yemelyanova; Anthony M Magliocco; Mollie A Finkel; Tracy E Moore; Premal H Thaker
Journal:  Cancer       Date:  2021-11-17       Impact factor: 6.921

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.